COLUMBIA, Md., Jan. 12 /PRNewswire/ -- Cylex Incorporated® announced today that the American Medical Association (AMA) CPT Editorial Panel approved the creation of new CPT coding based on the uniqueness, clinical value and widespread use of ImmuKnow, and the fact that existing CPT codes insufficiently captured all steps and costs of testing.
In an effort to keep customers informed of these changes, the following new information is now available:
"We are very pleased by the decision of the AMA to recognize the value of ImmuKnow as a biomarker that provides valuable insight for individualized patient management by establishing a unique CPT code," said President, CEO and Chairman Brad L. Stewart. "We look forward to assisting clinicians with continuing to expand the implementation of ImmuKnow as standard of care in more effectively managing their patients' immunosuppression."
ImmuKnow is a biomarker of immune function that complements immunomodulatory therapy and helps physicians and other healthcare professionals more effectively manage immunosuppression in posttransplant patients, thereby reducing the risks of infection and rejection by:
ImmuKnow is the FDA-cleared assay that tracks changes in global immune function over time.
*CPT = Current Procedural Terminology
ImmuKnow is a noninvasive biomarker of immune function that assesses cellular immune status by detecting cell-mediated immunity (CMI) in adult immunosuppressed patients. It measures the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation. The ImmuKnow assay is a qualitative assay and does not directly quantify the level of immunosuppression. Results of the ImmuKnow assay should be used in conjunction with clinical presentation, medical history, and other clinical indicators when assessing the immune status of any individual patient. ImmuKnow is increasingly being adopted at organ transplant centers throughout the United States and abroad.
About Cylex, Inc.
Cylex is the commercial global life sciences company leading the development and manufacture of in vitro diagnostic assays that measure cellular immune function. The Company's unique technology detects cell-mediated immunity, which presents an exciting opportunity for development of additional assays for diseases, and companion diagnostics for treatments, that affect the immune system. ImmuKnow, its first commercial product, is an FDA-cleared, noninvasive biomarker of immune function which is utilized by clinicians to more effectively manage and optimize immunosuppression in organ transplant patients. Cylex is a Technology Fast 500™ award winner for 2009, Deloitte LLP's ranking of 500 of the fastest growing technology companies in North America. The Company is based in Columbia, MD USA.
SOURCE Cylex, Inc.
|SOURCE Cylex, Inc.|
Copyright©2010 PR Newswire.
All rights reserved